Cargando…
Adherence to Phosphodiesterase Type 5 Inhibitors in the Treatment of Erectile Dysfunction in Long-Term Users: How Do Men Use the Inhibitors?
INTRODUCTION: The high effectiveness of phosphodiesterase type 5 inhibitors (PDE5-i) in the treatment of erectile dysfunction (ED) has been demonstrated. However, previous research shows that PDE5-i treatments have high discontinuation rates. AIM: The main goals of this study were to (i) characteriz...
Autores principales: | Carvalheira, Ana, Forjaz, Vera, Pereira, Nuno Monteiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184679/ https://www.ncbi.nlm.nih.gov/pubmed/25356304 http://dx.doi.org/10.1002/sm2.31 |
Ejemplares similares
-
Carotid artery intima media thickness can predict the response to phosphodiesterase 5 inhibitors in patients with moderate erectile dysfunction
por: Kilic, Metin, et al.
Publicado: (2023) -
Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis
por: Shin, Young Eun, et al.
Publicado: (2023) -
Endothelial Dysfunction in Patients With Erectile Dysfunction: A Double-Blind, Randomized-Control Trial Using Tadalafil
por: Pattanaik, Smita, et al.
Publicado: (2019) -
Effect of Icariside II and Metformin on Penile Erectile Function, Histological Structure, Mitochondrial Autophagy, Glucose-Lipid Metabolism, Angiotensin II and Sex Hormone in Type 2 Diabetic Rats With Erectile Dysfunction
por: Zhang, Jian, et al.
Publicado: (2020) -
The Daily Therapy With L-Arginine 2,500 mg and Tadalafil 5 mg in Combination and in Monotherapy for the Treatment of Erectile Dysfunction: A Prospective, Randomized Multicentre Study
por: Gallo, Luigi, et al.
Publicado: (2020)